It seems that all the power players in the arena are in search of how medicinal Cannabis science will be advanced going forward. Hence the need for the professionals such as Dr. Padma-Nathan to the medicinal rescue with questions and answers regarding efficacy and risk verses the actual benefits of cannabinoids.
Dr. Padma-Nathan serves as a member of the editorial board of the Journal of Cardiovascular Pharmacology & Therapeutics
Cardiovascular Pharmacology & Therapeutics, was a prior editor of International Journal of Impotence Research and a reviewer for several peer-reviewed urology and cardiovascular medical journals. Those that attended the conference hope Dr. Padma-Nathan will continue to offer education and enlightenment regarding the clinical use of cannabinoids and the benefits they bring to the medical Cannabis / cannabinoid consumer.
Dr. Padma-Nathan suggests the gaps in the health care and the non-health care industry
include the scientific data, scientific trials, drug delivery and how cannabinoids can be utilized in a clinical setting. Apparently, the FDA has the same concerns as only a few states will be able to administer and prescribe the new approved seizure drug, Epidiolex.
Medical cost was not mentioned by Dr. Padma-Nathan however, many at the conference were having a mounting conversation on the cost of a legalized cannabinoid, marijuana / Cannabis in general. The FDA offered it also remains to be seen how this approval will affect insurance coverage for epileptic patients seeking CBD oil type treatments. At a new (legal) Texas dispensary that made headlines for treating a 2-year-old boy with epilepsy, a 7.5-milliliter bottle of Epidiolex costs $105, and is not up for any insurance coverage to date. The conference panel did discuss patient care however; what the cost could mushroom to in terms of healthcare cost was absent. The state of California recently added the new long-awaited requirement and rules that stipulate all cannabis products must be sold in child-resistant packaging and must be lab-tested for potency for a variety of contaminants to include mold & E-coli.
dosage form and through a reproducible route of delivery to ensure that patients derive the anticipated benefits” (FDA, 2018).